IDEXX Laboratories, Inc. (NASDAQ:IDXX) is one of the 10 best healthcare equipment stocks to buy according to hedge funds. On February 9, David Westenberg from Piper Sandler maintained his Overweight rating on IDEXX Laboratories, Inc. (NASDAQ:IDXX). The analyst reduced the target price from $775 to $750, which results in a revised upside of 18%. Westenberg’s downward revision of the price target is based on Piper Sandler’s updated multiple for the stock. It also incorporates 2026 projections that have been ...

IDEXX Laboratories, Inc. (NASDAQ:IDXX) is one of the best pet stocks to buy according to hedge funds. On February 9, Piper Sandler cut the price target on IDEXX Laboratories, Inc. (NASDAQ:IDXX) to $750 from $775 while maintaining a Neutral rating on the shares. The rating update came after the company’s quarterly results, with the firm telling investors that its updated price target primarily takes into account its updated multiple and rolling forward of estimates to 2027 from 2026. Jim Cramer on IDEXX La ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 01-0393723 (State or other jurisdiction of ...

Investors looking for stocks in the Medical - Instruments sector might want to consider either SONOVA HOLDING (SONVY) or Idexx Laboratories (IDXX) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The Zacks Rank is a proven strategy that targets companies with positive e ...

Core Viewpoint - Idexx Laboratories is highlighted as a promising investment opportunity in the pet industry, particularly due to its innovative products and strong recurring revenue model [1][2]. Group 1: Company Overview - Idexx Labs is a leading provider of diagnostic tests and Software-as-a-Service offerings for the animal health industry, significantly aiding veterinarians [2]. - The company has achieved total returns of 20% annually since 1994, transforming an initial investment of $5,000 into $1.6 million today [2]. Group 2: Revenue Model - Idexx's business model is characterized by recurring revenue streams from its medical instruments and veterinary services, with 92% of its consumer animal group's sales being recurring in the most recent quarter [4][5]. - The company has over 164,500 medical instruments installed globally, generating consistent cash flow through VetLab consumables and reference lab diagnostics [4]. Group 3: Product Innovation - The recent launch of the InVue DX instrument is noted as one of the most successful product launches in Idexx's history, with nearly 6,400 placements in its first year [6]. - InVue DX has the potential to test for various cancer types in pets, with capabilities already being tested for canine lymphoma in the U.S. and planned international rollout [6].

Conestoga Capital Advisors, an asset management company, released its fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. In Q4 2025, Conestoga Capital Advisors Mid Cap Strategy returned -5.75% net of fees compared to the Russell Midcap Growth Index’s -3.70% return. The underperformance was driven by negative stock selection in the Technology and Industrials sectors, while positive sector allocation effects partially eased underperformance. The Mid Cap Composite returned -4.73% ...

Core Insights - IDEXX Laboratories, Inc. is a global leader in pet healthcare innovation and will participate in two upcoming conferences [1] Conference Participation - The company will have a fireside chat at the virtual BofA Securities Animal Health Conference on February 26, from 9:55 am to 10:30 am EST [1]

Core Insights - Baron Partners Fund achieved a significant return of 19.07% in Q4 2025, outperforming both the Russell Midcap Growth Index (-3.70%) and the Russell 3000 Index (2.40%) [1] - For the entire calendar year of 2025, the Fund returned 24.86%, again outperforming the Russell Midcap Growth Index (8.66%) and the Russell 3000 Index (17.15%) [1] - The Fund focuses on long-term investments in a non-diversified portfolio of well-managed growth businesses across various market caps [1] Company Highlights: IDEXX Laboratories, Inc. - IDEXX Laboratories, Inc. is a US-based healthcare company with a market capitalization of $51.73 billion, specializing in products for veterinary diagnostics and testing in various industries [2] - As of February 10, 2026, IDEXX's stock closed at $646.53 per share, with a 41.36% increase over the past twelve months, despite a recent decline of -9.00% in the past month [2] - The company has introduced new tests in 2025, with another expected in 2026, and has reported better-than-expected financial results, contributing positively to the Fund's performance [3] - IDEXX's competitive trends are viewed as outstanding, with expectations for proprietary innovations to drive future growth, supported by increasing trends in pet ownership and spending [3] - The stock appreciated 63.6% in 2025, indicating strong market performance [3]

Core Thesis - IDEXX Laboratories, Inc. is experiencing strong financial performance and growth, driven by its leadership in veterinary diagnostics and a robust recurring revenue model [6]. Financial Performance - For Q4 2025, IDEXX reported revenue of $1.09 billion, a 14% increase year-over-year, with organic growth of 12% and EPS of $3.08, surpassing the consensus estimate of $2.93 [3][4]. - Full-year revenue reached $4.30 billion, reflecting a 10% increase both reported and organically, with EPS of $13.08, marking a 14% increase over 2024 [3][4]. - The company generated $1.1 billion in free cash flow for 2025, fully converting net income to cash, and returned $1.2 billion to shareholders through share repurchases [5]. Growth Drivers - The Companion Animal Group (CAG) was the primary growth engine, generating $998 million in Q4 revenue with 13% organic growth, driven by recurring diagnostic revenue and volume gains [4]. - IDEXX set a quarterly record with over 1,900 inVue Dx instruments placed, contributing to 69% organic growth in CAG Diagnostic instrument revenues [4]. - Other segments, including Water and Livestock, Poultry & Dairy, also performed well, with organic growth of 10% and 4% respectively [5]. Future Outlook - IDEXX expects 2026 revenue to be between $4.63 billion and $4.72 billion, reflecting 7% to 9% organic growth, and EPS of $14.29 to $14.80, supported by continued margin expansion [5]. - Strategic investments in innovation, such as the inVue Dx platform and CancerDx test, are anticipated to drive future growth [5].

Core Viewpoint - Baron Focused Growth Fund demonstrated strong performance in Q4 2025, significantly outperforming the Russell 2500 Growth Index, with a return of 12.34% compared to the index's 0.33% [1] Group 1: Fund Performance - The Fund achieved a total return of 22.26% in 2025, while the Russell 2500 Growth Index returned 10.31% [1] - As of December 31, 2025, the top 10 positions of the Fund accounted for 60.1% of net assets [1] Group 2: IDEXX Laboratories, Inc. Overview - IDEXX Laboratories, Inc. is a leading US-based healthcare company focused on diagnostics for the veterinary industry, benefiting from an increase in pet ownership during the COVID pandemic [3] - As of February 4, 2026, IDEXX's stock closed at $642.94 per share, with a market capitalization of $51.438 billion [2] - The stock experienced a -9.75% return in the past month but has increased by 39.60% over the past twelve months [2] Group 3: Investment Sentiment - IDEXX Laboratories, Inc. was held by 55 hedge fund portfolios at the end of Q3 2025, an increase from 48 in the previous quarter [4] - Despite recognizing IDEXX's potential, there is a belief that certain AI stocks may offer greater upside potential with less downside risk [4]